Pasithea Therapeutics Corp. (KTTA) is listed on NASDAQ in the Manufacturing sector. This page tracks real-time KTTA price, technical indicators including RSI, MACD, and the 52-week range, plus fundamentals, earnings history, and recent insider trading activity.
Technical Analysis
RSI (14) 52.4 Neutral
Market Cap $16.5M
Volume 22.8K
Fundamentals — 10-Q Q1 2026
Revenue --
Net Income $-2.9M
EPS $-0.12
P/E Ratio -4.1x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Coastlands Capital LP | 10% Owner | Buy | 100,000 | $0.53 | $53,000 | 2026 Jun 17 |
| Marques Tiago | Chief Executive Officer | Buy | 33,333 | $0.75 | $25,000 | 2025 Nov 28 |
| Dumesnil Simon | Director | Buy | 33,333 | $0.75 | $25,000 | 2025 Nov 28 |
| Steinman Lawrence | Director | Buy | 133,333 | $0.75 | $100,000 | 2025 Nov 28 |
| Marques Tiago | Chief Executive Officer | Sell | 960 | $0.83 | $797 | 2025 May 12 |
| Steinman Lawrence | Director | Buy | 30,000 | $0.43 | $12,900 | 2023 Jun 2 |
| Concord IP2 Ltd. | Insider | Buy | 1,000 | $1.11 | $1,110 | 2022 Oct 17 |
| Shahinian Eric | Insider | Buy | 64,357 | $1.19 | $76,384 | 2022 Sep 29 |
| Camac Capital, LLC | Insider | Buy | 88,901 | $1.13 | $100,573 | 2022 Sep 6 |
| Camac Fund, LP | Insider | Buy | 22,828 | $1.15 | $26,352 | 2022 Aug 30 |
| Geller Avi | Insider | Buy | 54,644 | $1.30 | $71,037 | 2022 Aug 19 |
| Shahinian Eric | Insider | Buy | 155,773 | $1.21 | $188,485 | 2022 Aug 17 |
Take KTTA further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put KTTA in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Pasithea Therapeutics Corp. next reports.
Set alerts on KTTA
Get notified when Pasithea Therapeutics Corp. hits your price targets or technical conditions are met.
Get Started Free